VivoSeq
Oncology

Resectable Sarcoma

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Resectable Sarcoma is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

40/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Withdrawn2 · 40%
Completed2 · 40%
Unknown status1 · 20%

Clinical Trials

Trial Activity

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT03397186
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
Unknown status·CCBA Research·Phase 1·NCT03002805·46 enrolled
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Completed·MMassachusetts General Hospital·Phase 2·NCT02448537·42 enrolled
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Withdrawn·IItalian Sarcoma Group·Phase 1·NCT03782363
Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.
Completed·—·Phase 1·NCT04802070·7 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)